Sketching the historical development of pyrimidones as the inhibitors of the HIV integrase
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15310%2F15%3A33157531" target="_blank" >RIV/61989592:15310/15:33157531 - isvavai.cz</a>
Alternative codes found
RIV/61389030:_____/15:00447199
Result on the web
<a href="http://www.sciencedirect.com/science/article/pii/S0223523414006114" target="_blank" >http://www.sciencedirect.com/science/article/pii/S0223523414006114</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.ejmech.2014.07.005" target="_blank" >10.1016/j.ejmech.2014.07.005</a>
Alternative languages
Result language
angličtina
Original language name
Sketching the historical development of pyrimidones as the inhibitors of the HIV integrase
Original language description
Heterocyclic substances perform a very unique role in drug design and discovery. This article provides the primary objectives of the analysis within pyrimidine centered new heterocyclic elements chronologically from their finding focusing on one of the essential enzyme of HIV virus particle that is integrase upon suppressing its strand transfer function. The class of compounds reviewed here includes bicyclic pyrimidines, dihydroxypyrimidines, pyrimidine-2,4-dinones, N-methylpyrimidones, pyranopyrimidine, pyridine-quinoline conjugates, pyrimidine-2-carboxamides, N-3 hydroxylated pyrimidine-2,4-diones as well as their various substituted analogues. Such initiatives released an effective drug Raltegravir as a first FDA approved anti-HIV integrase inhibitor as well as several of its derivatives along with other pyrimidones is under clinical or preclinical growth. Some of the provided scaffolds indicated dual anti-HIV efficacies against HIV reverse transcriptase and integrase enzymes at bot
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
CC - Organic chemistry
OECD FORD branch
—
Result continuities
Project
<a href="/en/project/LO1204" target="_blank" >LO1204: Sustainable development of research in the Centre of the Region Haná</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2015
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
European Journal of Medicinal Chemistry
ISSN
0223-5234
e-ISSN
—
Volume of the periodical
97
Issue of the periodical within the volume
JUN
Country of publishing house
FR - FRANCE
Number of pages
15
Pages from-to
649-663
UT code for WoS article
000356734600047
EID of the result in the Scopus database
—